Aripiprazole
Product Images NDC 17856-0100

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 17856-0100). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Atlantic Biologicals Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Case Label)

This is a description of Aripiprazole tablets, USP with a dosage of 15mg per tablet. The packaging comes with 100 tablets and bears important information such as GTIN, expiration date, and lot number. It is advised to store the tablets at a temperature between 20°C-25°C (68°F-77°F) with excursions permitted between 15°C-30°C (58°F-86°F). The label also includes a reminder to keep the medication out of reach of children. For indications and dosage schedules, reference the package insert. The tablets are distributed by Atanic Biologics Corp. in Miami, FL, with a contact number provided for reordering.*

FDA Label Image

Figure 3 (Aripiprazole 3figure)

FDA Label Image

Aripiprazole-fig-6.jpg (Aripiprazole Fig 6)

This text shows a comparison between Aripiprazole and a placebo in terms of proportion with relapse over time. It includes the number of subjects at risk in each group along with the days from randomization. The data can be used to evaluate the effectiveness of Aripiprazole in preventing relapse compared to a placebo in a clinical trial.*

FDA Label Image

Aripiprazole-fig-9.jpg (Aripiprazole Fig 9)

This text provides information on the least-squares mean change in YGTSS Total TIC score from baseline for Aripiprazole Low, Aripiprazole High, and Placebo groups over different weeks of treatment. The graph depicts the changes in scores over time.*

FDA Label Image

Figure 7 (Aripiprazole Figur7)

This text provides data on the proportion of subjects experiencing relapse with the medication Aripiprazole compared to placebo over a period of days from randomization. The number of subjects at risk for relapse is also included for each treatment group at different time points.*

FDA Label Image

Aripiprazole-figure1.jpg (Aripiprazole Figure1)

This text provides information on the effect of other drugs on Aripiprazole metabolism. It includes data on drugs such as ketoconazole, cimetidine, carbamazepine, famotidine, and valproate on Aripiprazole's fold change and relative change in pharmacokinetic parameters. The text also mentions CYP1A inhibitor, CYP2D6 inhibitor, and VP34 inducer in relation to Aripiprazole.*

FDA Label Image

Figure 2 (Aripiprazole Figure2)

This text discusses the effect of other drugs on the medication Aripiprazole. It mentions various factors such as enzymes, inducers, and blockers that can affect the absorption or metabolism of Aripiprazole. Specific drugs like valproate, lorazepam, and gastric acid blockers are discussed for their possible interactions with Aripiprazole. The text provides information on the percentage of change in the drug's activity when used in combination with other medications compared to when used alone.*

FDA Label Image

Figure 4 (Aripiprazole Figure4)

This text mentions information related to special populations such as metabolic status, age range, hepatic impairment, and renal impairment. It also includes data on gender and age categories. The text appears to refer to the evaluation of specific parameters for a drug or substance labeled as "Arpiprazole Fold Change."*

FDA Label Image

Figure 5 (Aripiprazole Figure5)

FDA Label Image

Structure (Aripiprazole Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.